Acceleron Pharma Inks $30M

Cambridge, Mass.-based Acceleron Pharma Inc. has raised $30 million in financing. The company said that strategic partner Celgene contributed to the round, along with “all other existing investors.” Acceleron has raised capital from Advanced Technology Ventures, Alkermes, Avalon Ventures, Bessemer Ventures, Celgene, Flagship Ventures, MPM BioEquities, OrbiMed Advisors, Polaris Ventures, QVT Financial, Sutter Hill Ventures and Venrock. The new funds will be used to expand the company’s clinical stage pipeline.

Celgene Buying Gloucester Pharma For Up To $640 Million

Celgene Corp. (Nasdaq: CELG) has agreed to acquire Gloucester Pharmaceuticals, a Cambridge, Mass.-based developer of oncology drugs. The deal is valued at up to $640 million, including a $340 million up-front cash payment and up to $300 million in earn-outs. Gloucester Pharma had raised over $130 million in VC funding, from firms like Apple Tree Partners, Novo AS, ProQuest Investments, Prospect Venture Partners and Rho Ventures.

PEHUB Community

Join the 12502 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

Psst! Got any hot tips?

  • This field is for validation purposes and should be left unchanged.

PE HUB News Briefs

RSS Feed Widget

Marketplace

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget

Reuters VC and PE feed

RSS Feed Widget